ALT Altimmune, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1326190 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY105.0%
TTM net income YoY7.3%
TTM EPS YoY25.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-230,461.0%
Net margin-214,861.0%
FCF margin—
EBITDA margin-230,187.8%
Returns
ROE-50.6%
ROA-42.0%
ROIC (approx.)-49.4%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets19.7%
Debt / equity0.15x
Current ratio18.55x
Interest coverage-57.76x
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio-9.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $41,000 | $20,000 | $426,000 | -$68,000 | $4.41M |
| R&D expense | $66.43M | $82.23M | $65.80M | $70.54M | $74.54M |
| SG&A expense | $28.10M | $20.97M | $18.14M | $17.13M | $15.41M |
| Operating income | -$94.49M | -$103.17M | -$95.93M | -$87.74M | -$96.91M |
| Interest expense | $1.64M | $9,000 | $35,000 | $8,000 | $5,000 |
| Pretax income | -$88.77M | -$95.06M | -$88.45M | -$84.91M | -$97.09M |
| Income tax | -$681,000 | — | — | -$197,000 | — |
| Net income | -$88.09M | -$95.06M | -$88.45M | -$84.71M | -$97.09M |
| EBITDA | -$94.38M | -$102.93M | -$95.45M | -$87.25M | -$96.36M |
| EPS (basic) | -1.00 | -1.34 | -1.66 | -1.81 | -2.35 |
| EPS (diluted) | -1.00 | -1.34 | -1.66 | -1.81 | -2.35 |
| Weighted avg. shares (diluted) | 88.10M | 71.00M | 53.25M | 46.93M | 41.28M |
| Balance sheet | |||||
| Cash & equivalents | $43.76M | $36.97M | $135.16M | $111.13M | $190.34M |
| Short-term investments | $229.70M | $94.97M | $62.70M | $73.78M | — |
| Current assets | $278.19M | $137.25M | $209.63M | $192.81M | $204.13M |
| PP&E, net | $312,000 | $413,000 | $651,000 | $1.08M | $1.45M |
| Intangibles | — | $0 | $0 | $12.42M | $12.42M |
| Total assets | $279.93M | $139.31M | $210.64M | $206.93M | $218.87M |
| Current liabilities | $15.00M | $10.47M | $12.14M | $17.05M | $18.28M |
| Long-term debt | $34.29M | — | — | $4.58M | $1.45M |
| Total debt | $34.29M | — | — | $4.58M | $1.45M |
| Total liabilities | $55.04M | $15.80M | $16.54M | $21.64M | $19.73M |
| Shareholders' equity | $224.89M | $123.51M | $194.10M | $185.29M | $199.13M |
| Net debt | -$9.47M | — | — | -$106.55M | -$188.88M |
| Shares outstanding | 110.88M | 72.35M | 70.68M | 49.20M | 40.99M |
| Cash flow statement | |||||
| Operating cash flow | -$67.53M | -$79.85M | -$75.81M | -$62.59M | -$78.24M |
| Capital expenditure | $11,000 | — | $47,000 | $126,000 | $12.12M |
| Free cash flow | -$67.55M | — | -$75.86M | -$62.71M | -$90.36M |
| Investing cash flow | -$132.47M | -$28.39M | $13.73M | -$73.40M | $87.52M |
| Financing cash flow | $206.84M | $10.04M | $86.11M | $56.78M | $65.10M |
| Depreciation & amortization | $112,000 | $238,000 | $477,000 | $493,000 | $551,000 |
| Stock-based compensation | $16.08M | $14.39M | $10.64M | $8.10M | $5.52M |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.